Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 2
2020 3
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Mainly Post-Transplant Factors Are Associated with Invasive Aspergillosis after Allogeneic Stem Cell Transplantation: A Study from the Surveillance des Aspergilloses Invasives en France and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Robin C, Cordonnier C, Sitbon K, Raus N, Lortholary O, Maury S, Peffault de la Tour R, Bretagne S, Bastuji-Garin S; SAIF (Surveillance des Aspergilloses Invasives en France) and the SFGM-TC (Société Francophone de Greffe de Moelle et de Thérapie Cellulaire) Aspergillus Group. Robin C, et al. Biol Blood Marrow Transplant. 2019 Feb;25(2):354-361. doi: 10.1016/j.bbmt.2018.09.028. Epub 2018 Sep 27. Biol Blood Marrow Transplant. 2019. PMID: 30268782 Free article. Clinical Trial.
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Le Bourgeois A, et al. Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274. Ann Oncol. 2017. PMID: 28911060 Free article.
HLA haplotype frequencies and diversity in patients with hemoglobinopathies.
Scigliuolo GM, Boukouaci W, Cappelli B, Volt F, Rivera Franco MM, Dhédin N, de Latour RP, Devalck C, Dalle JH, Castelle M, Hermine O, Chardin MO, Poiré X, Brichard B, Paillard C, Rafii H, Kenzey C, Wu CL, Bouassida J, Robin M, Raus N, Rocha V, Ruggeri A, Gluckman E, Tamouza R; Eurocord and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC). Scigliuolo GM, et al. EJHaem. 2023 Aug 4;4(4):963-969. doi: 10.1002/jha2.763. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024588 Free PMC article.
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study.
Bossard JB, Beuscart JB, Robin M, Mohty M, Barraco F, Chevallier P, Marchand T, Rubio MT, Charbonnier A, Blaise D, Bay JO, Botella-Garcia C, Damaj G, Beckerich F, Ceballos P, Cluzeau T, Cornillon J, Meunier M, Orvain C, Duhamel A, Garnier F, Kiladjian JJ, Yakoub-Agha I; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), the France-Intergroupe des Syndromes Myéloprolifératifs (FIM) and the Agence de la BioMédecine (ABM). Bossard JB, et al. Am J Hematol. 2021 Jan;96(1):80-88. doi: 10.1002/ajh.26034. Epub 2020 Nov 18. Am J Hematol. 2021. PMID: 33108024 Free article. Clinical Trial.
HLA-matched related donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: Comparison of myeloablative and non-myeloablative approaches.
Dhedin N, Chevillon F, Castelle M, Lavoipière V, Vasseur L, Dalle JH, Joseph L, Beckerich F, Buchbinder N, Coman T, Garban F, Ferster A, Nguyen S, Boissel N, Arlet JB, Pondarre C; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Dhedin N, et al. Am J Hematol. 2022 Sep;97(9):E359-E362. doi: 10.1002/ajh.26656. Epub 2022 Jul 23. Am J Hematol. 2022. PMID: 35802796 Free article. No abstract available.
Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC.
Longval T, Leprêtre AC, Ravinet A, Fayard A, Forcade E, Coman T, Redjoul R, Berceanu A, Buchbinder N, Berlie G, Mappoura M, Giannotti F, Chevillon F, Robin M, Peffault de Latour R, Sicre de Fontbrune F; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Longval T, et al. Bone Marrow Transplant. 2024 Mar 9. doi: 10.1038/s41409-024-02202-9. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38461290 No abstract available.
Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor.
Deteix C, Mesnil F, Furst S, Milpied N, Yakoub-Agha I, Fegueux N, Latour RP, Mohty M, Chevallier P, Labussière Wallet H, Huynh A, Larosa F, Bourhis JH, Cahn JY, Chantepie S, Bay JO, Audat F, Foote A, Faucher C, Marry E, Garban F; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Deteix C, et al. Bone Marrow Transplant. 2020 Apr;55(4):749-757. doi: 10.1038/s41409-019-0722-y. Epub 2019 Oct 29. Bone Marrow Transplant. 2020. PMID: 31664184
HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation.
Ducreux S, Dubois V, Amokrane K, Yakoub-Agha I, Labalette M, Michallet M, Rubio MT, Kennel A, Forcade E, Lafarge X, Bulabois CE, Masson D, Daguindau E, Devys A, Moalic V, Quelvennec E, Boudifa A, Picard C, Van Endert P, de Matteis M, Delbos F, Filloux M, Pedron B, Renac V, Hau F, Bonneau J, Parissiadis A, Fort M, Dormoy A, Maillard N, Jollet I, Chevallier P, Cesbron A, Bay JO, Quainon F, Garnier F, Socié G, Loiseau P, Porcher R, Peffault de Latour R; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI). Ducreux S, et al. Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25133. Online ahead of print. Am J Hematol. 2018. PMID: 29726580 Free article.
Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC.
Le Bourgeois A, Labopin M, Marçais A, de Latour RP, Blaise D, Chantepie S, N'Guyen S, Maillard N, Forcade E, Yakoub-Agha I, Huynh A, Marchand T, Bilger K, Ceballos P, Charbonnier A, Turlure P, Rubio MT, Béné MC, Guillaume T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Le Bourgeois A, et al. Ann Hematol. 2020 Aug;99(8):1855-1862. doi: 10.1007/s00277-020-04074-7. Epub 2020 Jun 20. Ann Hematol. 2020. PMID: 32564196 Clinical Trial.
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Le Bourgeois A, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, Orvain C, Wallet HL, Bilger K, Blaise D, Rubio MT, Guillaume T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Le Bourgeois A, et al. Oncotarget. 2018 Nov 27;9(93):36603-36612. doi: 10.18632/oncotarget.26391. eCollection 2018 Nov 27. Oncotarget. 2018. PMID: 30564300 Free PMC article.